RXi Pharmaceuticals Corporation
257 Simarano Drive, Suite 101 | Marlborough, MA 01752
August 28, 2017
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
Attn: | Christopher Edwards |
Re: | RXi Pharmaceuticals Corporation |
Registration Statement on FormS-1 (File No. 333-220062) |
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, RXi Pharmaceuticals Corporation (the “Company”) hereby requests that the effective date of the above-captioned registration statement (the “Registration Statement”) be accelerated so that it becomes effective at 4:00 p.m., Eastern Time, on August 30, 2017, or as soon thereafter as practicable.
Please call Ryan Murr of Gibson, Dunn & Crutcher LLP at (415)393-8373 as soon as the Registration Statement has been declared effective.
Very truly yours, | ||
RXi PHARMACEUTICALS CORPORATION | ||
By: | /s/ Geert Cauwenbergh | |
Name: | Geert Cauwenbergh, Dr. Med. Sc. | |
Title: | President, Chief Executive Officer and Chief Financial Officer |